ReProtect  Products to protect reproductive health

About ReProtect
Contact ReProtect
Site Map


Expected February 2009 Results of the Phase II/IIB HIV Prevention trial of BufferGel and PRO 2000 are expected to be announced in February.
June 2006 Phase II study of BufferGel®-Duet™ for therapy of bacterial vaginosis therapy agreed to, anticipated initiation in Q2, 2007
October 2005

Duet Phase I safety and acceptability study completed: BufferGel with Duet safe, acceptable, and fit 97% of trial participants

July 2005 BufferGel Phase III contraceptive trials completed: Demonstrated contraceptive efficacy and safety of BufferGel plus diaphragm
June 2005 Received NIH funding for further development of Duet device design and manufacturing
Feb 2005 Phase II/IIB HIV prevention trial of BufferGel and PRO 2000 begins
May 2004 With Starphama Holdings Ltd, received NIH funding for creation of a second generation microbicide based on BufferGel combined with Starpharma’s “dendrimer” technology.

Half Daisy

Last updated 11/24/08  |  Legal Information  |  Copyright ReProtect Inc., 2003-2008